Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 4Completed 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Myeloid, Chronic-Phase 1

Interventions

fludarabine phosphate 140Cyclophosphamide 132Busulfan 102Peripheral Blood Stem Cell Transplantation 95Imatinib Mesylate 94Mycophenolic Acid 91Cytarabine 82Azacitidine 80Tacrolimus 79Cyclosporine 78Whole-Body Irradiation 77fludarabine 74Antilymphocyte Serum 71Methotrexate 65Filgrastim 63nilotinib 59Melphalan 51Decitabine 49Radiotherapy 43Dasatinib 34Granulocyte Colony-Stimulating Factor 33ruxolitinib 31Clofarabine 31Etoposide 30thymoglobulin 29Thiotepa 29Cord Blood Stem Cell Transplantation 28sargramostim 27Methylprednisolone 26Stem Cell Transplantation 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × olverembatinib × Myeloid × Clear all
NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Ascentage Pharma Group Inc.

Phase 2 Completed
144 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04126707 2021-09-08

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Ascentage Pharma Group Inc.

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡